netFormulary Central Lancashire Formulary NHS
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley and South Ribble CCG
Greater Preston CCG
 
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Please refer to appropriate antibiotic Guidelines:

LTHTr Antibiotic Guidelines

 Details...
05.01  Antibacterial drugs
05.01  Table 1. Summary of antibacterial therapy
05.01  Table 2. Summary of antibacterial prophylaxis
05.01.01  Penicillins
05.01.01.01  Benzylpenicillin and phenoxymethylpenicillin to top
05.01.01.02  Penicillinase-resistant penicillins
05.01.01.03  Broad-spectrum penicillins
05.01.01.04  Antipseudomonal penicillins
05.01.01.05  Mecillinams
05.01.02  Cephalosporins, carbapenems and other beta-lactums to top
05.01.02  Cephalosporins
05.01.02  Other beta-lactam antibiotics
05.01.02.01  Cephalosporins
05.01.02.02  Carbapenems
05.01.02.03  Other beta-lactums antibiotics to top
05.01.03  Tetracyclines
05.01.03  Tigecycline
05.01.04  Aminoglycosides
05.01.05  Macrolides
05.01.06  Clindamycin to top
05.01.07  Some other antibacterials
05.01.07  Chloramphenicol
05.01.07  Fosfomycin
05.01.07  Fusidic acid
05.01.07  Vancomycin and teicoplanin to top
05.01.07  Daptomycin
05.01.07  Linezolid
05.01.07  Quinupristin and dalfopristin
05.01.07  Polymyxins
05.01.07  Rifaximin to top
05.01.07  Fidaxomicin
05.01.08  Sulphonamides and trimethoprim
05.01.09  Antituberculosis drugs
05.01.10  Antileprotic drugs
05.01.11  Metronidazole and tinidazole to top
05.01.12  Quinolones
05.01.13  Urinary-tract infections
05.02  Antifungal drugs
05.02  Treatment of fungal infections
05.02  Drugs used in fungal infections to top
05.02.01  Triazole antifungals
05.02.02  Imidazole antifungals
05.02.03  Polyene antifungals
05.02.04  Echinocandin antifungals
05.02.05  Other antifungals to top
05.03  Antiviral drugs
05.03.01  HIV infection
05.03.01  Nucleoside reverse transcriptase inhibitors
05.03.01  Protease inhibitors
05.03.01  Non-nucleoside reverse transcriptase inhibitors to top
05.03.01  Other antiretrovirals
05.03.02  Herpesvirus infections
05.03.02.01  Herpes simplex and varicella-zoster infection
05.03.02.02  Cytomegalovirus infection
05.03.03  Viral hepatitis to top
05.03.03.01  Chronic hepatitis B
05.03.03.02  Chronic hepatitis C
05.03.04  Influenza
05.03.05  Respiratory syncytial virus
Palivizumab (Synagisģ)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Respiratory syncytial virus in infants

• To reduce the risk of respiratory syncytial virus (RSV) in infants with bronchopulmonary dysplasia (BPD) (also known as chronic lung disease) for the 18/19 season - Blueteq approval

• To reduce the risk of respiratory syncytial virus (RSV) in infants with congenital heart disease (CHD) for the 18/19 season - Blueteq approval

• to reduce the risk of respiratory syncytial virus (RSV) in infants with severe combined immunodeficiency syndrome (SCID) for the 18/19 season - Blueteq approval

 
   
05.04  Antiprotozoal drugs to top
05.04.01  Antimalarials
05.04.01  Treatment of malaria
05.04.01  Falciparum malaria (treatment)
05.04.01  Benign malarias (treatment)
05.04.01  Prophylaxis against malaria to top
05.04.01  Specific recommendations
05.04.01  Artemether with lumefabtrine
05.04.01  Chloroquine
05.04.01  Mefloquine
05.04.01  Primaquine to top
05.04.01  Proguanil
05.04.01  Pyrimethamine
05.04.01  Quinine
05.04.01  Tetracyclines
05.04.02  Amoebicides to top
05.04.03  Trichomonacides
05.04.04  Antigiardial drugs
05.04.05  Leishmaniacides
05.04.06  Trypanocides
05.04.07  Drugs for toxoplasmosis to top
05.04.08  Drugs for pneumocystis pneumonia
05.04.08  Treatment
05.04.08  Prophylaxis
05.05  Anthelmintics
05.05.01  Drugs for threadworms to top
05.05.02  Ascaricides
05.05.03  Drugs for tapeworm infections
05.05.03  Taenicides
05.05.03  Hydatid disease
05.05.04  Drugs for hookworms to top
05.05.05  Schistosomicides
05.05.06  Filaricides
05.05.07  Drugs for cutaneous larva migrans
05.05.08  Drugs for strongyloidiasis
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Little or no specific monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Brief prescribing document or information sheet may be required.  

Amber 1

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Minimal monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Full prior agreement about patientís on-going care must be reached under the shared care agreement.  

Amber 2

Initiated by specialist and transferred to primary care following a successful initiation period. Significant monitoring required on an on-going basis. Full prior agreement about patientís on-going care must be reached under the shared care agreement. Suitable for enhanced service.  

Black

NOT recommended for use by the NHS in Lancashire. Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.  

Blue

Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information  

Green

Appropriate for initiation and ongoing prescribing in both primary and secondary care. Generally, little or no routine drug monitoring is required.  

Purple

Low Priority for Prescribing - see Low Priority for Prescribing Policy  

Red

Medicine is supplied by the hospital for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.  

Red Specialist Centre

Prescribing restricted to Specialist Centres only  

netFormulary